We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Olá - Rio is calling!
Save the date for our PVRI 2025 Congress, which will be held in Rio de Janeiro, Brazil, from Wednesday 29 January - Sunday 2 February 2025.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Webinar presentations: Autoantibodies as the cause of pulmonary arterial hypertension, Pulmonary hypertension in myelodysplastic syndrome, Prevalence and effect of myelofibrosis on pulmonary arterial hypertension, Mast cells as the cause of pulmonary vascular remodeling in pulmonary arterial hypertension, B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary hypertension, Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodeling
Ladakh, a land of spirituality with mystic Lamas and a traveller’s paradise with mighty mountains and high passes with their splendid beauty, welcomes you to the 7th International Leh Symposium 2024 with a theme on ‘Molecular mechanisms and therapeutics of hypoxic lung’.
Organised by the leaders of the PVRI LATAM Task Force, the meeting will address the latest advances in diagnosis and management of adult and paediatric PH and explore avenues to increase the partnership of adult and paediatric physicians to improve clinical outcomes and quality of life for PH patients across the entire lifespan.
Webinar presentations: Therapeutic efficacy and mechanisms of Drpitor1a in PAH; SNPs for sirtuin3 and uncoupling protein2 are causal of PAH and diabetes disease severity; Mitochondrial control of metabolic, angiogenic, and hematopoietic function in PH onset and progression; Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with PH.
This retrospective study was conducted to evaluate all-cause healthcare resource utilization (HCRU) and costs in commercially insured patients living with pulmonary arterial hypertension (PAH) and explore end-of-life (EOL)-related HCRU and costs.
Parameters of cardiopulmonary exercise testing significantly discriminate between healthy subjects and patients with pulmonary hypertension (PH), also according to the new 2022 definition of pulmonary hypertension (mean pulmonary arterial pressure mPAP > 20 mmHg).
The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School invites applications for an advanced fellowship in pulmonary heart disease starting 1 July 2025.
Cereno Scientific, a pioneering biotech developing innovative treatments for rare and common cardiovascular diseases, has joined PVRI as a Roundtable member.
The announcement that many of you have been waiting for...drumroll please...our PVRI 2025 Congress will be held in Rio de Janeiro, Brazil, from Wednesday, 29 January, to Sunday, 2 February 2025. Save the date!
Rupert Swift, a brave, bold, clever, charismatic young man who embraced life to the full, developed high altitude pulmonary oedema and 3 months later, was diagnosed with functional class 3 pulmonary hypertension.
